The Clorox Company $CLX Shares Purchased by ProShare Advisors LLC

ProShare Advisors LLC boosted its position in shares of The Clorox Company (NYSE:CLX) by 11.7% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 1,297,016 shares of the company’s stock after acquiring an additional 136,135 shares during the period. ProShare Advisors LLC’s holdings in Clorox were worth $159,922,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Savvy Advisors Inc. increased its stake in shares of Clorox by 1.4% in the 2nd quarter. Savvy Advisors Inc. now owns 6,395 shares of the company’s stock valued at $768,000 after purchasing an additional 91 shares in the last quarter. Canandaigua National Bank & Trust Co. grew its holdings in Clorox by 0.8% in the third quarter. Canandaigua National Bank & Trust Co. now owns 11,196 shares of the company’s stock valued at $1,380,000 after purchasing an additional 94 shares during the period. State of Michigan Retirement System grew its holdings in Clorox by 0.3% in the second quarter. State of Michigan Retirement System now owns 33,551 shares of the company’s stock valued at $4,028,000 after purchasing an additional 100 shares during the period. Blue Trust Inc. increased its position in shares of Clorox by 8.5% in the third quarter. Blue Trust Inc. now owns 1,333 shares of the company’s stock valued at $164,000 after buying an additional 104 shares in the last quarter. Finally, Westhampton Capital LLC raised its stake in shares of Clorox by 0.5% during the 3rd quarter. Westhampton Capital LLC now owns 23,150 shares of the company’s stock worth $2,854,000 after buying an additional 107 shares during the period. Institutional investors and hedge funds own 78.53% of the company’s stock.

Clorox Stock Up 1.6%

Shares of NYSE CLX opened at $119.52 on Monday. The stock has a market cap of $14.45 billion, a PE ratio of 19.53, a P/E/G ratio of 0.59 and a beta of 0.59. The company has a current ratio of 0.74, a quick ratio of 0.48 and a debt-to-equity ratio of 71.03. The Clorox Company has a 12-month low of $96.66 and a 12-month high of $159.04. The company has a 50-day moving average of $105.83 and a 200 day moving average of $113.73.

Clorox (NYSE:CLX) last issued its earnings results on Tuesday, February 3rd. The company reported $1.39 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.04). The company had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.64 billion. Clorox had a return on equity of 383.01% and a net margin of 11.17%.The company’s revenue for the quarter was down .8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.55 earnings per share. As a group, sell-side analysts predict that The Clorox Company will post 7.15 EPS for the current fiscal year.

Clorox Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Wednesday, January 28th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 4.1%. The ex-dividend date is Wednesday, January 28th. Clorox’s dividend payout ratio is presently 81.05%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on CLX shares. TD Cowen lifted their price target on shares of Clorox from $108.00 to $111.00 and gave the company a “hold” rating in a research note on Wednesday, February 4th. Wall Street Zen upgraded shares of Clorox from a “sell” rating to a “hold” rating in a research report on Saturday. UBS Group upped their price target on shares of Clorox from $115.00 to $121.00 and gave the stock a “neutral” rating in a research report on Wednesday. Royal Bank Of Canada set a $132.00 price objective on Clorox in a report on Wednesday. Finally, The Goldman Sachs Group cut their price objective on Clorox from $110.00 to $94.00 and set a “sell” rating for the company in a research note on Wednesday, January 7th. One equities research analyst has rated the stock with a Buy rating, ten have assigned a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $117.93.

Key Headlines Impacting Clorox

Here are the key news stories impacting Clorox this week:

• Positive Sentiment: Morgan Stanley raised its price target on CLX to $136 (maintained equal-weight), citing valuation/earnings dynamics — a catalyst supporting the stock’s rally. Clorox (NYSE:CLX) Price Target Raised to $136.00 at Morgan Stanley
• Positive Sentiment: Investor write-ups are bullish: a Seeking Alpha piece frames CLX as a defensive, dividend-rich value after “solid” Q2 results and attractive valuation — supporting buy interest from income-focused investors. Clorox: Solid Q2 Results And Cheap Valuation MakesThis Defensive Dividend Stock A Strong Buy
• Neutral Sentiment: TD Cowen nudged its price target to $111 and kept a Hold rating — a modest recalibration that tempers upside expectations despite the recent positive headlines. TD Cowen Adjusts Clorox Price Target
• Neutral Sentiment: Company reported mixed Q2 results and reaffirmed its 2026 outlook — revenue roughly flat year-over-year and an EPS miss by a few cents; reassurances on the outlook limit downside but leave questions on near-term margin recovery. Clorox Posts Mixed Q2 Results, Reaffirms 2026 Outlook
• Neutral Sentiment: Management is weighing a potential GOJO acquisition and finishing an ERP implementation; strategic moves could boost long-term growth but add execution risk in the near term. Clorox Weighs GOJO Deal And ERP Finish Against Softer Earnings
• Neutral Sentiment: Q2 earnings call transcript is available for deeper read on management commentary around pricing, cost savings and margin plans — useful for gauging execution risk. Clorox (CLX) Q2 2026 Earnings Call Transcript
• Negative Sentiment: Some brokerages have a consensus “Reduce” rating on CLX, which may cap upside as institutional flows react to conservative guidance and margin concerns. The Clorox Company Given Consensus Rating of “Reduce” by Brokerages
• Negative Sentiment: BofA flagged margin uncertainty after the Q2 EPS miss — a reminder that cost and margin recovery, not just revenue, will drive forecast revisions and investor sentiment. BofA Flags Margin Uncertainty for Clorox After Q2 Earnings Miss
• Neutral Sentiment: A Zacks piece highlights using its Earnings ESP tool to find staples stocks that might beat — general market research, not CLX-specific guidance, but could affect short-term trading interest. Why Investors Need to Take Advantage of These 2 Consumer Staples Stocks Now

Insider Activity

In related news, Director Pierre R. Breber bought 4,000 shares of the business’s stock in a transaction on Friday, November 21st. The stock was acquired at an average cost of $104.13 per share, with a total value of $416,520.00. Following the purchase, the director directly owned 13,000 shares of the company’s stock, valued at $1,353,690. The trade was a 44.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.63% of the stock is owned by company insiders.

About Clorox

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.